# IBL Data Sheet

Code No. 18257

**Anti-Rat**
**GRO/CINC-1 (N) Rabbit IgG Affinity Purify**

Volume : 100 µg

**Introduction** : Growth Related Oncogene (GRO) /Cytokine-induced neutrophil chemo attractant 1 (CINC-1) was originally purified from media conditioned by IL-1βstimulated rat kidney epithelioid cells (NRK-52E). Amino acid sequence that encodes for rat CINC-1 was identified in 1989 by Watanabe's group at Toyama Medical and Pharmaceutical University. CINC-1 is a member of the alpha (CXC) subfamily of chemokines. Three additional rat CXC chemokines (CINC-2α, CINC-2β, CINC-3/MIP-2) have been identified. The protein sequence of CINC-1 is 63 - 67% identical to that of CINC-2α, CINC-2β, CINC-3/MIP-2. In addition, GROα, GROβ and GROγ is sharing 68%, 71% and 69%, identity with CINC-1. This has been suggested that CINCs are the rat counterpart of human GROs.

**Antigen** : Synthetic peptides of the N-terminal part of rat GRO/CINC-1

**Purification** : Purified with antigen peptide

**Form** : Lyophilized product in PBS

**How to use** : 1.0 mL deionized water will be added to the product (the conc. comes up 100 µg /mL)

**Stability** : Lyophilized product, 5 years at 2 – 8 °C
: Solution, 2 years at –20 °C

**Application** : This antibody can be used for immunohistochemistry with formalin fixed paraffin embedded tissues by several techniques such as Avidin Biotin Complex (ABC) Method. The optimal concentration is about 2 – 5 µg/mL, however, the concentration should be optimized by each laboratory.
: This antibody can be used for western blotting in concentration of 2 - 5 µg /mL.

**Neutralization Activity** : Inhibits migration of neutrophil (up to 6 nM) at 10 µg/mL (inhibits up to 10 nM when use with #18256)

**Specificity** : Not cross-react with rat GRO/CINC-2α, -2β, -3.

**Reference** : Koike K., Sakamoto Y., Sawada T., Ohmichi M., Kanda Y., Nohara A., Hirota K., Kiyama H., and Miyake A. The production of CINC/gro, a member of the interleukin-8 family, in rat anterior pituitary gland. Biochem. Biophys. Res. Commun. (1994) 202, 161-167



**Immuno-Biological Laboratories Co., Ltd.** URL: http://www.ibl-japan.co.jp E-Mail: do-ibl@ibl-japan.co.jp